Skip to main content
. Author manuscript; available in PMC: 2012 May 31.
Published in final edited form as: Anticancer Agents Med Chem. 2011 Oct;11(8):729–738. doi: 10.2174/187152011797378689

Figure 1. Illustration depicting the use of various targeted approaches under development for the treatment of GBM.

Figure 1

A) The receptors (left) and their ligands (right) under development for targeted toxin therapies are shown. Various toxins (T) are linked to specific ligands in order to elicit the binding and internalization of the targeted toxins to receptors that are overexpressed on GBM cells. The rationale underlying the use of targeted toxins is shown in (B).